1. Admin, U. F. D. KEYTRUDA (pembrolizumab) injection, for intravenous use. (Prescrib. Inf., US Food Drug Admin., Silver Spring, MD., https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s066lbl.pdf, 2020).
2. Admin, U. F. D. Opdivo (nivolumab). (Drug. Inf., US Food Drug Admin., Silver Spring, MD., https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554, 2019).
3. Admin, U. F. D. Yervoy (ipilimumab). (Drug. Inf.,US Food Drug Admin., Silver Spring, MD, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377, 2019).
4. Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).
5. Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).